These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36831541)

  • 41. Clinical validity of tumor-infiltrating lymphocytes analysis in patients with triple-negative breast cancer.
    Pruneri G; Vingiani A; Bagnardi V; Rotmensz N; De Rose A; Palazzo A; Colleoni AM; Goldhirsch A; Viale G
    Ann Oncol; 2016 Feb; 27(2):249-56. PubMed ID: 26598540
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Predictive and prognostic value of stromal tumour-infiltrating lymphocytes before and after neoadjuvant therapy in triple negative and HER2-positive breast cancer.
    Ochi T; Bianchini G; Ando M; Nozaki F; Kobayashi D; Criscitiello C; Curigliano G; Iwamoto T; Niikura N; Takei H; Yoshida A; Takei J; Suzuki K; Yamauchi H; Hayashi N
    Eur J Cancer; 2019 Sep; 118():41-48. PubMed ID: 31302586
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Tumor-infiltrating lymphocytes predict survival in ≥ pT2 urothelial bladder cancer.
    Ledderose S; Rodler S; Eismann L; Ledderose G; Ledderose C
    Pathol Res Pract; 2022 Sep; 237():154037. PubMed ID: 35908386
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tertiary lymphoid structures: prognostic significance and relationship with tumour-infiltrating lymphocytes in triple-negative breast cancer.
    Lee HJ; Park IA; Song IH; Shin SJ; Kim JY; Yu JH; Gong G
    J Clin Pathol; 2016 May; 69(5):422-30. PubMed ID: 26475777
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Neoadjuvant chemotherapy (NACT) increases immune infiltration and programmed death-ligand 1 (PD-L1) expression in epithelial ovarian cancer (EOC).
    Mesnage SJL; Auguste A; Genestie C; Dunant A; Pain E; Drusch F; Gouy S; Morice P; Bentivegna E; Lhomme C; Pautier P; Michels J; Le Formal A; Cheaib B; Adam J; Leary AF
    Ann Oncol; 2017 Mar; 28(3):651-657. PubMed ID: 27864219
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical Validity and Utility of Tumor-Infiltrating Lymphocytes in Routine Clinical Practice for Breast Cancer Patients: Current and Future Directions.
    Wein L; Savas P; Luen SJ; Virassamy B; Salgado R; Loi S
    Front Oncol; 2017; 7():156. PubMed ID: 28824872
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Morphological Evaluation of Tumor-Infiltrating Lymphocytes (TILs) to Investigate Invasive Breast Cancer Immunogenicity, Reveal Lymphocytic Networks and Help Relapse Prediction: A Retrospective Study.
    Romagnoli G; Wiedermann M; Hübner F; Wenners A; Mathiak M; Röcken C; Maass N; Klapper W; Alkatout I
    Int J Mol Sci; 2017 Sep; 18(9):. PubMed ID: 28885584
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Correlation between
    Murakami W; Tozaki M; Sasaki M; Hida AI; Ohi Y; Kubota K; Sagara Y
    Eur J Radiol; 2020 Feb; 123():108773. PubMed ID: 31918248
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tumour-infiltrating lymphocytes (TILs)-related genomic signature predicts chemotherapy response in breast cancer.
    Kochi M; Iwamoto T; Niikura N; Bianchini G; Masuda S; Mizoo T; Nogami T; Shien T; Motoki T; Taira N; Tokuda Y; Doihara H; Matsuoka J; Fujiwara T
    Breast Cancer Res Treat; 2018 Jan; 167(1):39-47. PubMed ID: 28905250
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer.
    Luen SJ; Savas P; Fox SB; Salgado R; Loi S
    Pathology; 2017 Feb; 49(2):141-155. PubMed ID: 28049579
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ.
    Beguinot M; Dauplat MM; Kwiatkowski F; Lebouedec G; Tixier L; Pomel C; Penault-Llorca F; Radosevic-Robin N
    BMC Cancer; 2018 Feb; 18(1):129. PubMed ID: 29394917
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I-III patients treated with standard therapy.
    Dieci MV; Tsvetkova V; Griguolo G; Miglietta F; Tasca G; Giorgi CA; Cumerlato E; Massa D; Lo Mele M; Orvieto E; Guarneri V; Conte P
    Eur J Cancer; 2020 Sep; 136():7-15. PubMed ID: 32622323
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
    Kolberg-Liedtke C; Feuerhake F; Garke M; Christgen M; Kates R; Grischke EM; Forstbauer H; Braun M; Warm M; Hackmann J; Uleer C; Aktas B; Schumacher C; Kuemmel S; Wuerstlein R; Graeser M; Nitz U; Kreipe H; Gluz O; Harbeck N
    Breast Cancer Res; 2022 Sep; 24(1):58. PubMed ID: 36056374
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prediction of Treatment Response to Neoadjuvant Chemotherapy in Breast Cancer by Subtype Using Tumor-infiltrating Lymphocytes.
    Asano Y; Kashiwagi S; Goto W; Takada K; Takahashi K; Hatano T; Takashima T; Tomita S; Motomura H; Ohsawa M; Hirakawa K; Ohira M
    Anticancer Res; 2018 Apr; 38(4):2311-2321. PubMed ID: 29599354
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast.
    Pruneri G; Lazzeroni M; Bagnardi V; Tiburzio GB; Rotmensz N; DeCensi A; Guerrieri-Gonzaga A; Vingiani A; Curigliano G; Zurrida S; Bassi F; Salgado R; Van den Eynden G; Loi S; Denkert C; Bonanni B; Viale G
    Ann Oncol; 2017 Feb; 28(2):321-328. PubMed ID: 28426105
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Association of TILs with clinical parameters, Recurrence Score® results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.
    Kolberg-Liedtke C; Gluz O; Heinisch F; Feuerhake F; Kreipe H; Clemens M; Nuding B; Malter W; Reimer T; Wuerstlein R; Graeser M; Shak S; Nitz U; Kates R; Christgen M; Harbeck N
    Breast Cancer Res; 2020 May; 22(1):47. PubMed ID: 32408905
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic value of tumor-infiltrating lymphocytes in patients with triple-negative breast cancer: a systematic review and meta-analysis.
    Gao G; Wang Z; Qu X; Zhang Z
    BMC Cancer; 2020 Mar; 20(1):179. PubMed ID: 32131780
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prognostic significance of tumor-infiltrating lymphocytes in premenopausal, luminal breast cancer treated with adjuvant endocrine therapy.
    Zhang J; Abubakar M; Yuan P; Koka H; Guo L; Li X; Yang XR; Ying J; Lyu N
    Am J Transl Res; 2021; 13(11):12750-12762. PubMed ID: 34956490
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    Liu S; Chen B; Burugu S; Leung S; Gao D; Virk S; Kos Z; Parulekar WR; Shepherd L; Gelmon KA; Nielsen TO
    JAMA Oncol; 2017 Nov; 3(11):e172085. PubMed ID: 28750133
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.